Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.
2 reports, 2 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Leerink partners and Cantor Fitzgerald issued new rating upgrades for Replimune Group, Inc.1 source
Cantor Fitzgerald lowered its shares rating on Replimune Group, Inc.1 source
Keep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Leerink partners
U.S. investment bank
Related events
- Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.
- Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.
- Cantor Fitzgerald raised its price target and gave an overweight rating for SOL Strategies Inc. on October 11, 2026.
- Cantor Fitzgerald issued a neutral rating and price target, while Sherry Group Inc. significantly increased its share holdings on October 10, 2026.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.